ディサ―ナ・ファ―マシュ―ティカルズ（DRNA）Dicerna Pharmaceuticals Inc. - 米国株銘柄紹介

DRNAのチャート

DRNAの企業情報

symbol	DRNA
会社名	Dicerna Pharmaceuticals Inc （ディサ―ナ・ファ―マシュ―ティカルズ）
分野（sector）	Health Care ヘルスケア
産業（industry）	Major Pharmaceuticals
業種	バイオテクノロジ―_メディカルリサ―チ医療関連（Health Care）
概要	事業概要 Dicerna Pharmaceuticals Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET). ディサ―ナ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。肝臓の遺伝性疾患などの癌のためのRNA干渉技術プラットフォ―ムを使用した治療法の発見と開発に焦点を当てる。同社は、｢DCR-PH1｣と｢DCR-M1711｣製品を開発している。また癌遺伝子キルステンラット肉腫ウイルス癌遺伝子ホモログを対象に開発する。
本社所在地	87 Cambridgepark Drive Cambridge MA 02140 USA
代表者氏名	David M. Madden David M. Madden
代表者役職名	Independent Chairman of the Board
電話番号	+1 617-621-8097
設立年月日	38991
市場名	NASDAQ National Market System
ipoyear	2014年
従業員数	44人
url	www.dicerna.com
nasdaq_url	https://www.nasdaq.com/symbol/drna
adr_tso	―
EBITDA	EBITDA（百万ドル） -59.59300
終値（lastsale）	14.19
時価総額（marketcap）	877039981.95
時価総額	時価総額（百万ドル） 837.03670
売上高	売上高（百万ドル） 4.98200
企業価値(EV)	企業価値(EV)（百万ドル） 763.63970
当期純利益	当期純利益（百万ドル） -93.17100
決算概要	決算概要 BRIEF: For the six months ended 30 June 2018 Dicerna Pharmaceuticals Inc revenues increased from $0K to $3.1M. Net loss applicable to common stockholders increased 34% to $51.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Litigation expense increase from $2.2M to $22.2M (expense).

DRNAのテクニカル分析

DRNAのニュース

FDA accepts Lilly and Dicerna's cardiometabolic diseases IND 2021/05/27 11:37:19 Seeking Alpha

How Messed Up Can Things Be 2021/05/27 04:37:33 Seeking Alpha

Leerink Partners Stick to Their Buy Rating for Dicerna Pharma By Investing.com 2021/04/08 20:25:12 Investing.com

Leerink Partners Stick to Their Buy Rating for Dicerna Pharma

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront 2021/04/08 13:04:05 Benzinga

Royalty Pharma plc (NASDAQ: RPRX ) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA ) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. The FDA and European Medicines Agency have approved … Full story available on Benzinga.com

Dicerna's RNAi Technology Shows Encouraging Action Against CNS Targets In Animal Studies 2021/03/30 13:59:00 Benzinga

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced new data from preclinical studies of its GalXC-Plus RNAi technology …

Leerink Partners Stick to Their Buy Rating for Dicerna Pharma By Investing.com 2021/03/02 00:00:03 Investing.com

Leerink Partners Stick to Their Buy Rating for Dicerna Pharma

The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida 2021/02/26 13:16:52 Benzinga

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.